Cited by 315Muscle Physiology and DisordersNutrition and Health in AgingBone Metabolism and Diseases

RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass

Open access
Bonnet, Nicolas, Bourgoin, Lucie, Biver, Emmanuel, Douni, Eleni, Ferrari, Serge·2019·Journal of Clinical Investigation

Abstract

Receptor activator of Nfkb ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits, osteoclastogenesis. In turn a neutralizing Ab against RANKL, denosumab improves bone strength in osteoporosis. OPG also improves muscle strength in mouse models of Duchenne's muscular dystrophy (mdx) and denervation-induce atrophy, but its role and mechanisms of action on muscle weakness in other conditions remains to be investigated. We investigated the effects of RANKL inhibitors on muscle in osteoporotic women and mice that either overexpress RANKL (HuRANKL-Tg+), or lack Pparb and concomitantly develop sarcopenia (Pparb-/-). In women, denosumab over 3 years improved appendicular lean mass and handgrip strength compared to no treatment, whereas bisphosphonate did not. HuRANKL-Tg+ mice displayed lower limb force and maximal speed, while their leg muscle mass was diminished, with a lower number of type I and II fibers. Both OPG and denosumab increased limb force proportionally to the increase in muscle mass. They markedly improved muscle insulin sensitivity and glucose uptake, and decrease anti-myogenic and inflammatory gene expression in muscle, such as myostatin and protein tyrosine phosphatase receptor-γ. Similarly, in Pparb-/-, OPG increased muscle volume and force, while also normalizing their insulin signaling and higher expression of inflammatory genes in skeletal muscle. In conclusions, RANKL deteriorates, while its inhibitor improves, muscle strength and insulin sensitivity in osteoporotic mice and humans. Hence denosumab could represent a novel therapeutic approach for sarcopenia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci125915

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Osteokines are novel exercise-inducible soluble factors secreted by osteocytes, osteoblasts, and osteoclasts that play an important role in the body's response to exercise, mainly including RANKL, sclerostin, osteocalcin, FGF23, Wnt3a, TGF-β, IGF-1, and PGE2.

    “Osteokines, novel exercise-inducible soluble factors secreted by osteocytes, osteo blasts, and osteoclasts, play an important role in the body’s response to exercise, mainly including RANKL [127], sclerostin [128], osteocalcin [129], fibroblast growth factor 23 (FGF23) [95], Wnt3a [130], TGF-β [131], IGF-1 [132], and prostaglandin E2 (PGE2) [133] (Figure 3).”
  • RANKL inhibition improves muscle strength and insulin sensitivity in osteoporotic mice and humans through the RANK/RANKL/OPG signaling pathways, potentially representing a new therapeutic avenue for sarcopenia.

    “Research has shown that RANKL inhibition improves muscle strength and insulin sensitivity in osteoporotic mice and humans through the RANK/RANKL/OPG signaling pathways, potentially representing a new therapeutic avenue for sarcopenia [127].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Park HJ, Baek K, Baek JH, Kim HR. TNFα increas- es RANKL expression via PGE 2 -induced activa- tion of NFATc1. Int J Mol Sci. 2017;18(3):495.

Cited by

Sorted by citations

Authors
Bonnet, N., Bourgoin, L., Biver, E., Douni, E., & Ferrari, S.
Affiliations
  • University Hospital of Geneva (CH)
  • Agricultural University of Athens (GR)
Corresponding author
Bonnet, Nicolas
Venue
Journal of Clinical Investigation
Published
2019-07-02
Volume
129
Issue
8
Pages
3214-3223
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2945787015
Cited by
314
References
41
Citations by year
2026: 39 · 2025: 48 · 2024: 42 · 2023: 48 · 2022: 45 · 2021: 46 · 2020: 36 · 2019: 10
FWCI
11.34
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Funders
  • Swiss National Science Foundation grant (No 3100A0-116633/1)
  • European Foundation for the Study of Diabetes (ME1598)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
RANKL inhibition, denosumab, osteoprotegerin, muscle strength, insulin sensitivity, sarcopenia, osteoporosis, PPARδ, muscle atrophy, muscle fiber composition, myostatin, PTEN, skeletal muscle glucose uptake, muscle inflammation, bisphosphonates, osteoclastogenesis
MeSH terms
Denosumab, Animals, Bone and Bones, Cell Line, Female, Humans, Insulin Resistance, Male, Mice, Transgenic, Organ Size, Osteoporosis, PPAR-beta, Mice, Osteoprotegerin, RANK Ligand, Muscle Strength, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review